TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product
Highlights Granted Patent covers the design of VIVI Cap Smart™ across major international, growing market Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic discussions with appliance manufacturers Design term extends through May 16, 2039 Company enters into f
Technology, Biotechnology, Pharmaceuticals, Health
2026-05-14 3:00 AM EDT | TempraMed Technologies Ltd.
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceu
Biotechnology, Pharmaceuticals, Health
2026-05-13 5:32 PM EDT | BioHarvest Sciences Inc.
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 49% owned by PharmaTher and 51% owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF), is pursuing its strategic plans to focus on the clinical development of its patented enteric-coated oral Cepharanthine ("PD-001") as a potential therapeutic candidate
Biotechnology, Pharmaceuticals
2026-05-13 10:11 AM EDT | PharmaTher Holdings Ltd.
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is is pleased to announce that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 51% owned by PharmaDrug and 49% owned by PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher"), is pursuing its strategic plans to focus on the clinical devel
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2026-05-13 8:50 AM EDT | PharmaDrug Inc.
BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
- CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals - In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition Vancouver, British Colum
Biotechnology, Pharmaceuticals, Health
2026-05-13 8:00 AM EDT | BioHarvest Sciences Inc.
Restart Life Sciences Leverages Amazon Logistics for Strategic Entry of Holy Crap Foods into U.S. Market
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc., is preparing for its official entry into the United States market. This expansion marks a pivotal milestone in the Company's North American growth strategy under its new leadership team. While the brand previously maintained a broader internatio
Technology, Biotechnology, Health
2026-05-13 6:00 AM EDT | Restart Life Sciences Corp.
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated April 22, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 13,600,000 units (e
Biotechnology, Pharmaceuticals, Health
2026-05-12 5:02 PM EDT | PreveCeutical Medical Inc.
DIMERx Preclinical Data Confirms DMX-101 Non-Addictive Profile: No Reinforcement, No Dependence
San Francisco, California--(Newsfile Corp. - May 12, 2026) - DIMERx, Inc. ("DIMERx" or "the Company") is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug misuse and dependence, with a portfolio of first-
Biotechnology, Pharmaceuticals, Health
2026-05-12 9:00 AM EDT | DIMERx INC.
BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 12, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has s
Biotechnology, Pharmaceuticals, Health
2026-05-12 7:30 AM EDT | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing tec
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-12 7:00 AM EDT | Phio Pharmaceuticals Corp.
Zenith Capital Corp. Amends Promissory Notes
Calgary, Alberta--(Newsfile Corp. - May 12, 2026) - Zenith Capital Corp. ("Zenith" or the "Company") today announces the amendment of an aggregate amount of US$11.1 million and CAD$6.7 million of promissory notes (the "Notes") held by an immediate family member (the "Lender") of Zenith's Chairman and CEO and entities controlled by the Lender to: (i) increase the interest rate for all Notes from 11% to 18% per annum, commencing effective February 1, 2026, (ii) to grant the Lender conversion pr
2026-05-12 12:40 AM EDT | Zenith Capital Corp.
Resverlogix Announces One-Year Extension of Debenture
Calgary, Alberta--(Newsfile Corp. - May 11, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a one-year extension of the Company's US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2027. In connection with the extension, the interest rate has been amended from 18% to 20% per annum, commencing on May 14, 2026. "
Technology, Biotechnology, Healthcare and Hospitals
2026-05-11 5:15 PM EDT | Resverlogix Corp.
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - May 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that advance the Company another step closer toward commercialization of its investigational Acclaim® cochlear implant. "The first quarter of 2026 marked a transformative period for Envoy Medical, highlighted
Biotechnology, Healthcare and Hospitals
2026-05-11 8:00 AM EDT | Envoy Medical, Inc.
American Aires Inc. Announces Updates on Annual Filings, Litigation and Listing Matters, Cease Trade Order, and 2024 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 8, 2026) - American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the "Company") announces that further to the Company's news releases dated April 7, 2026 and April 17, 2026, it will not file its audited annual financial statements for the fiscal year ended December 31, 2025, together with the related management's discussion and analysis and CEO and CFO certifications (collectively, the "Required Filings"), because the audited financial statem
2026-05-08 6:00 PM EDT | American Aires Inc.
Restart Life Sciences Announces Dedicated Purchase Order Financing Through Private Placement Offering
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce a purchase order ("PO") financing arrangement that will establish a revolving source of dedicated capital to support the sourcing, manufacturing, and fulfillment activities of its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"). The financing will be offered as a non-brokered private placement o
Technology, Biotechnology, Health
2026-05-08 10:30 AM EDT | Restart Life Sciences Corp.
Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce the strategic expansion of its internal operations team as the Company accelerates the scaling of its "better-for-you" functional food and Consumer Packaged Goods (CPG) portfolio. To support its growth trajectory, the Company has added a specialized Project Manager to its internal leadership team. Rep
Technology, Biotechnology, Health
2026-05-08 9:00 AM EDT | Restart Life Sciences Corp.
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline of small molecules for the treatment of retinal diseases. First Quarter 2026 and Recent Highlights Enrollment in the Phase 2 ABACUS-2 study of KIO-301 remains very active, with expansion of clinical trial sites to accommodat
Biotechnology, Pharmaceuticals
2026-05-08 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended March 31, 2026, and provided a busine
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-07 4:05 PM EDT | Phio Pharmaceuticals Corp.
Restart Life Sciences Appoints Capital Markets Veteran Lindsay Hamelin to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce the appointment of Lindsay Hamelin as an Independent Director of the Company, effective immediately. Ms. Hamelin brings over 20 years of capital markets and corporate finance experience, with a specific expertise in corporate structuring, mergers and acquisitions, and financing strategies within publi
Technology, Biotechnology, Health
2026-05-07 6:00 AM EDT | Restart Life Sciences Corp.
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026 which ended March 31, 2026. The Company's full financial statements and related MD&A for the third
Biotechnology, Pharmaceuticals
2026-05-06 6:00 PM EDT | InMed Pharmaceuticals